Susceptibility and resistance to depression is determined by the actions of the stimuli provoking it, including stressors and inflammatory processes, as well as the activity of the body’s protective systems, such as neurotrophins and antiapoptotic proteins. To clarify the effects of stressor and proinflammatory actions inducing a depression-like state on these protective mechanisms, we studied the role of the level of mRNA for brain-derived neurotrophic factor (BDNF) and antiapoptotic protein Bcl-xL in parts of the brain in adult male rats after 14 days of stressor (forced swimming or restricted mobility) or proinflammatory (administration of lipopolysaccharide, LPS) treatments. Both stressors significantly decreased BDNF expression in the midbrain; the decrease in neurotrophin expression in the cortex was significant after swimming but at the level of a tendency after restriction of mobility. After LPS, the level of BDNF mRNA decreased significantly in the hippocampus, but not in the midbrain – the areas in which stressors have influences. Both stressors increased Bcl-xL mRNA levels in the brainstem but produced reductions in the midbrain, with no change in other areas. LPS had no effect on Bcl-xL expression in most areas but decreased it in the brainstem, where the level of this transcript correlated negatively with the adrenal index. Overall, stressor and proinflammatory treatments induced changes in Bcl-xL expression unique to each treatment and even in opposite directions (in the brainstem). The prodepressive actions of both LPS and stressors were associated with decreases in BDNF expression located in brain areas specific for each treatment: in the hippocampus in the case of LPS and in the midbrain and prefrontal cortex in the case of stressors. These features of the responses of BDNF and Bcl-xL point to significant differences in the pathways of induction of psychoemotional pathology by stress and activation of inflammation.
Similar content being viewed by others
References
M. Stepanichev, N. N. Dygalo, G. Grigoryan, et al., “Rodent models of depression: neurotrophic and neuroinflammatory biomarkers,” Biomed. Res. Int., 2014, 932757 (2014).
R. Dantzer, “Cytokine, sickness behavior, and depression,” Immunol. Allergy Clin. North Am., 29, 247–264 (2009).
M. Adzic, Z. Brkic, M. Mitic, et al., “Therapeutic strategies for treatment of inflammation-related depression,” Curr. Neuropharmacol., 16, 176–209 (2018).
B. E. Leonard, “Inflammation and depression: a causal or coincidental link to the pathophysiology?” Acta Neuropsychiatr., 30, 1–16 (2018).
C. H. Liu, G. Z. Zhang, B. Li, et al., “Role of inflammation in depression relapse,” J. Neuroinflammation, 16, 90 (2019).
J. Lasselin, “Is inflammation-associated depression atypical depression?” Brain Behav. Immun. (2020) (Epub ahead of print).
G. M. Slavich, B. M. Way, N. I. Eisenberger, and S. E. Taylor, “Neural sensitivity to social rejection is associated with inflammatory responses to social stress,” Proc. Natl. Acad. Sci. USA, 107, 14817–14822 (2010).
T. Takemura, S. Makino, T. Takao, et al., “Hypothalamic-pituitaryadrenocortical responses to single vs. repeated endotoxin lipopolysaccharide administration in the rat,” Brain Res., 767, 181–191 (1997).
V. Grinevich, X. M. Ma, J. P. Herman, et al., “Effect of repeated lipopolysaccharide administration on tissue cytokine expression and hypothalamic-pituitary-adrenal axis activity in rats,” J. Neuroendocrinol., 13, 711–723 (2001).
A. S. Elgarf, S. Aboul-Fotouh, H. A. Abd-Alkhalek, et al., “Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model of depression in rats: reversibility by imipramine and pentoxifylline,” Pharmacol. Biochem. Behav., 126, 152–162 (2014).
J. E. Finnell and S. K. Wood, “Putative inflammatory sensitive mechanisms underlying risk or resilience to social stress,” Front. Behav. Neurosci., 12, 240 (2018).
R. S. Duman and L. M. Monteggia, “A neurotrophic model for stressrelated mood disorders,” Biol. Psychiatry, 59, 1116–1127 (2006).
V. Krishnan and E. J. Nestler, “The molecular neurobiology of depression,” Nature, 455, 894–902 (2008).
M. Sairanen, G. Lucas, P. Ernfors, et al., “Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus,” J. Neurosci., 25, 1089–1094 (2005).
N. V. Gulyaeva, “Molecular mechanisms of neuroplasticity: an expanding universe,” Biochemistry (Mosc.), 82, 237–242 (2017).
M. Wurzelmann, J. Romeika, and D. Sun, “Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury,” Neural Regen. Res., 12, 7–12 (2017).
R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nat. Rev. Mol. Cell. Biol., 9, 47–59 (2008).
G. T. Shishkina, T. S. Kalinina, I. V. Berezova, et al., “Resistance to the development of stress-induced behavioral despair in the forced swim test associated with elevated hippocampal Bcl-xl expression,” Behav. Brain Res., 213, 218–224 (2010).
E. A. Jonas, G. A. Porter, and K. N. Alavian, “Bcl-xL in neuroprotection and plasticity,” Front. Physiol., 5, 355 (2014).
H. D. Fulenwider, B. M. Smith, A. S. Nichenko, et al., “Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation,” J. Neuroinflammation, 15, 60 (2018).
R. Dang, X. Zhou, M. Tang, et al., “Fish oil supplementation attenuates neuroinflammation and alleviates depressive-like behavior in rats submitted to repeated lipopolysaccharide,” Eur. J. Nutr., 57, 893–906 (2018).
K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)). Method,” Methods, 25, No. 4, 402–408 (2001).
S. Dal-Zotto, O. Martí, and A. Armario, “Influence of single or repeated experience of rats with forced swimming on behavioural and physiological responses to the stressor,” Behav. Brain Res., 114, 175–181 (2000).
X. T. Guan, W. J. Lin, and M. M. Tang, “Comparison of stress-induced and LPS-induced depressive-like behaviors and the alterations of central proinflammatory cytokines mRNA in rats,” Psych. J., 4, 113–122 (2015).
S. Chiba, T. Numakawa, M. Ninomiya, et al., “Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 39, 112–119 (2012).
E. Ampuero, A. Luarte, M. Santibañez, et al., “Two chronic stress models based on movement restriction in rats respond selectively to antidepressant drugs: aldolase c as a potential biomarker,” Int. J. Neuropsychopharmacol., 18, pyv038 (2015).
C. C. Martinez, F. Astort, J. M. Di Gruccio, et al., “Lipopolysaccharide stimulates adrenal steroidogenesis in rodent cells by a NFκB-dependent mechanism involving COX-2 activation,” Mol. Cell Endocrinol., 337, 1–6 (2011).
R. S. Duman, S. Deyama, and M. V. Fogaça, “Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants,” Eur. J. Neurosci. (2019), (Epub ahead of print).
M. Borsoi, C. B. Antonio, A. F. Viana, et al., “Immobility behavior during the forced swim test correlates with BNDF levels in the frontal cortex, but not with cognitive impairments,” Physiol. Behav., 140, 79–88 (2015).
L. Hritcu and L. D. Gorgan, “Intranigral lipopolysaccharide induced anxiety and depression by altered BDNF mRNA expression in rat hippocampus,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 51, 126–132 (2014).
M. Adachi, M. Barrot, A. E. Autry, et al., “Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy,” Biol. Psychiatry, 63, 642–649 (2008).
I. Allaman, M. Papp, R. Kraftsik, et al., “Expression of brain-derived neurotrophic factor is not modulated by chronic mild stress in the rat hippocampus and amygdala,” Pharmacol. Rep., 60, 1001–1007 (2008).
G. Naert, G. Ixart, T. Maurice, et al., “Brain-derived neurotrophic factor and hypothalamic-pituitary-adrenal axis adaptation processes in a depressive-like state induced by chronic restraint stress,” Mol. Cell. Neurosci., 46, 55–66 (2011).
N. Charoenphandhu, A. Nuntapornsak, K. Wongdee, et al., “Upregulated mRNA levels of SERT, NET, MAOB, and BDNF in various brain regions of ovariectomized rats exposed to chronic aversive stimuli,” Mol. Cell Biochem., 375, 49–58 (2013).
E. Scotton, R. Colombo, J. C. Reis, et al., “BDNF prevents central oxidative damage in a chronic unpredictable mild stress model: The possible role of PRDX-1 in anhedonic behavior,” Behav. Brain Res., 378, 112245 (2020).
D. P. McKernan, T. G. Dinan, and J. F. Cryan, “‘Killing the Blues’: a role for cellular suicide (apoptosis) in depression and the antidepressant response?” Prog. Neurobiol., 88, 246–263 (2009).
N. N. Dygalo, T. S. Kalinina, V. V. Bulygina, and G. T. Shishkina, “Increased expression of the anti-apoptotic protein Bcl-xL in the brain is associated with resilience to stress-induced depression-like behavior,” Cell. Mol. Neurobiol., 32, 767–776 (2012).
O. Malkesman, D. R. Austin, T. Tragon, et al., “Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants,” Mol. Psychiatry, 17, 770–780 (2012).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 106, No. 6, pp. 756–764, June, 2020.
Rights and permissions
About this article
Cite this article
Komysheva, N.P., Shishkina, G.T., Kalinina, T.S. et al. Features of the Responses of the Protective Systems of the Brain in Adult Rats to Stressors and Lipopolysaccharide. Neurosci Behav Physi 51, 367–371 (2021). https://doi.org/10.1007/s11055-021-01080-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-021-01080-8